Top 50 Biotechnology VC (Venture Capital) Funds in United States in May 2025
A list of 50 VC (Venture Capital) funds that invest in Biotechnology startups based in United states. We rank investors based on the number of investments they made in Biotechnology companies from United states. We update this investor list every month.Top 50 Biotechnology VC (Venture Capital) Funds in United States in May 2025
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
- Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, France
Portfolio highlights
- Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
- Hoofprint Biome — Hoofprint Biome, developing probiotics for to increase feed digestibility and decreasing methane in cattle
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Series C
- United States, India, Canada
Portfolio highlights
- Arkestro — Bid Ops is the only predictive procurement software built to keep your team continuously exceeding targets. Using Bid Ops, you can orchestrate your activities across systems using instant forecasts and real-time collaboration. Predict and win 2-5x faster savings and never get stuck waiting for a KPI report again. Learn more athttps://www.bidops.com
- Wonder — Introducing a new kind of home dining experience. Currently available in areas of New Jersey.
- Samaya AI — The company specializes in developing AI research agents that streamline knowledge workflows.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
- Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
- Health Care, Medical, Medical Device
- Seed, Pre-Seed, Convertible Note
- United States, Argentina, United Kingdom
Portfolio highlights
- Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
- HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
- iYOTAH Solutions — Take your dairy operation to the next level. Our state of the art platform helps you save time, increase efficiencies and profits and unlock new opportunities.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
- nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series A, Series C
- United States, Ireland, Singapore
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
- Auron Therapeutics — A differentiated approach to cure cancer.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Series B, Seed
- United States, India, United Kingdom
Portfolio highlights
- Somite — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
- Realta Fusion — Realta Fusion develops fusion energy technology for the production of industrial heat and power. It applies advances in super-conducting materials, plasma physics, and computing power to a simple linear fusion reactor configuration. It utilizes abundant fuel sources to provide a zero-carbon source of heat and power.
- Cartwheel — Cartwheel is a powerful new way to animate characters for videos, games, 3D, movies, ads or social media.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Post-IPO Equity
- United States, United Kingdom, Canada
Portfolio highlights
- Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
- Jade Biosciences — Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
- Imbria Pharmaceuticals — Imbria is a clinical-stage, cardio-metabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, United Kingdom, China
Portfolio highlights
- Dinari — Discover Equity Boundless - Simplify everything from equity management and options grant to payroll so that you no longer have to worry about compliance, taxes, or vesting schedules no matter where your employees are.
- Toku — Toku helps companies to automate collections and facilitate payment processes. Toku enables companies to optimize the collection of recurring payments.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United States, Canada
Portfolio highlights
- KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
- Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
- Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- WiseLayer — WiseLayer's AI empowers finance teams to improve profitability & efficiency in minutes per week
- Page — Page, an AI-powered external relations platform that provides real-time insights to help enterprises navigate government policies, media, and regulations.
- Wise Layer — WiseLayer makes AI-powered digital workers for finance and accounting teams.It's AI digital workforce includes: - Angela, the AI agent for Accruals & Rev Rec (hire her at www.accruals.ai) - Dennis, the AI agent for Discrepancies & Financial Anomalies (hire him at www.discrepancies.ai) - … with the 4 newest AI agents eachspecializingin the following tasks: (1) bank reconciliations, (2) fixed asset depreciation & amortization, (3) lease accounting, and (4) prepaid expenses.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- Hedra — Video creation for everyone.
- Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
- Sprinter Health — Sprinter Health is an on-demand mobile health company that sends full-time nurses and phlebotomists (“Sprinters”) into the home.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Saildrone — Saildrone is the world leader in oceangoing autonomous surface vehicles, providing unrivaled payload, range, and reliability from an uncrewed system.
- Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
- Jericho Security — Train your team to defend against the latest cyber attacks with our complete cybersecurity platform.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Lumafield — Lumafield's easy-to-use CT scanner and cloud-based software give engineers the ability to see their work clearly, inside and out.
- Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
- Alta Resource Technologies — Alta Resource Technologies is on a mission to reinvent mining by harnessing advanced biochemistry to cost-effectively source the critical raw materials needed to power next-generation technology and bolster economic security. Our groundbreaking technology platform leverages customizable proteins to separate high-purity rare earth elements and otheressential minerals with unprecedented selectivity while dramatically reducing the environmental impact of mining.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
- VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
- PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Veza — Veza is the identity security company that enables organizations to understand, manage and control who can and should take what action on what data.
- Blacksmith — Blacksmith is a company that helps businesses to conduct their continuous integration (CI) up to twice as quickly and at half the expense. Blacksmith accomplish this by running CI on powerful gaming CPUs.
- Glass Imaging — Traditional cameras rely on an imaging lens which typically consists of several lens elements and a light sensitive sensor. Cameras have been built like this since 1816. Glass has been historically used to make high quality optical elements. We are replacing these elements with deep neural networks that give extreme flexibility when designing ourcameras. It allows us to squeeze a huge sensor into an ultra thin module that fits perfectly into a mobile device without the need for protruding bumps. Our cameras bring SLR image quality into your pocket.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
- Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Post-IPO Equity
- United States, Canada, Ireland
Portfolio highlights
- Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
- New Amsterdam Pharma — We're advancing a new era of treatment for cardiovascular disease and other lipid-related conditions.
- Day One Biopharmaceuticals — Discover how Day One is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- Synaptrix — Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.
- AtaCor Medical — AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, France, Switzerland
Portfolio highlights
- Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Switzerland
Portfolio highlights
- TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
- Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
- TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Switzerland
Portfolio highlights
- NeuroBionics — NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate with the human body.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Esper Satellite Imagery — Esper is building and launching the world's most versatile satellite imagery network for mineral exploration, agronomy, and national security. Task imagery now.
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, Germany, Switzerland
Portfolio highlights
- D2B3 — The future of treating brain diseases.
- Alessa Therapeutics — We drive innovation in oncology and solid organ disease through development of advanced treatment and early interception.
- SiteOne Therapeutics — SiteOne develops selective inhibitors of sodium channels as non-opioid treatments to address acute and chronic pain
Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Artisan AI — Artisan is on a mission to build the first generation of AI employees, called Artisans, who can automate specific roles & workflows.
- TAU Systems — TAU Systems provides medical imaging technology.
- Foundation Alloy — Foundation Alloy makes better parts, faster, for modern engineering.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
- VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Seed, Series A
- United States, Israel, The Netherlands
Portfolio highlights
- Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
- Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
- Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
- Biotechnology, Health Care, Medical Device
- Angel, Seed, Series A
- United States, Canada, India
Portfolio highlights
- Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
- Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Canada, United Kingdom
Portfolio highlights
- Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
- Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
- Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.
Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.
Show more
Investment focus
- Software, Health Care, Information Technology
- Series A, Seed, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- Stord — Stord offers fulfillment, warehousing, and transportation for DTC and B2B, plus the integrated software you need to provide your end consumers with the best pre-purchase and post-delivery consumer experience. No matter your product, Stord is ready to power your commerce.
- NewLimit — NewLimit is extending human healthspan by unlocking regenerative potential.
- Persona — Online ID verification service to help any business, from any industry, collect, verify, and manage user identities throughout a customer lifecycle.
Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Series A, Series B
- United States, United Kingdom, New Zealand
Portfolio highlights
- Pilgrim — Pioneering a biologically enhanced future for humanity.
- Causal Labs — Causal Labs provides AI physics models to predict and control the weather.
- Remedy Scientific — Remedy decontaminates land with scalable, AI-driven systems, advanced chemistry and precise sensors, restoring sites to their full productive potential.
INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH
INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, Estonia
Portfolio highlights
- Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
- Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
- Fractyl Health — Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
The North Carolina Biotechnology Center is a private, non-profit corporation funded by the N.C. General Assembly to strengthen biotechnology research, business and education statewide. The Center is not a site for laboratory research; it works to support job creation in the biotechnology industry.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Debt Financing, Grant, Funding Round
- United States, United Kingdom
Portfolio highlights
- Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
- QATCH Technologies — Get the most out of a drop
- Atlantic Fish Company — Atlantic Fish Co is a cultivated seafood company using cellular agriculture to bring the world sustainable delicious seafood.
DIGITAL HEALTH / AI
DIGITAL HEALTH / AI GENE / CELL THERAPIES
NASDAQ: RCKT GENE / CELL THERAPIES
NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS
SYNTHETIC
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
- Alleviant Medical — Interventional therapy for congestive heart failure
- Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Funding Round
- United States, United Kingdom, Israel
Portfolio highlights
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, Canada, Denmark
Portfolio highlights
- Oculis — Experience the Future of Eye Care: Oculis, a Clinical Biopharmaceutical Innovator, Pioneering Breakthrough Treatments for Ophthalmic Diseases & Transforming Lives Globally.
- Bridge Medicines — MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the
- Sembiosys Genetics — SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts.
The firm operates as a multi-fund investment platform, covering growth equity, private
equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Post-IPO Equity
- United States, China, United Kingdom
Portfolio highlights
- 35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
- Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
- Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.
DCVC backs companies using deep tech to solve the biggest problems that matter. Our investments address climate change, human health, the operations of physically intensive industries, defense, security, space, and more.
Show more
Investment focus
- Biotechnology, Medical, Therapeutics
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- AgZen — At AgZen, we aim to revolutionize farming practices by providing real-time insights into droplet behavior. We empower growers with the tools to navigate agriculture's ever-changing landscape.
- Grove Biopharma — Grove is pioneering Bionic Biologics, a breakthrough synthetic drug modality that can penetrate cells and reach protein-protein interactions that drive disease.
- Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, United Kingdom, Canada
Portfolio highlights
- Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
- Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Investors by industry
Impact
Biotech
Gaming
FinTech
Google
Energy
Proptech
Marketplace
Consumer
Hardware
Artificial intelligence
Health Care
Climate
Community
EdTech
Sustainability
Venture Capital
Clean Energy
Real Estate
Financial Services
Video Games
B2B
Education
Publishing
Finance
Food and Beverage
Beauty
Infrastructure
Web3
Photography
Retail
Big Data
Organic Food
Payments
Social Media
Medical
Internet
Manufacturing
eSports
Construction
Digital Media
Art
Local
Sports
Music
Enterprise Software
Social Network
Wellness
Email
Franchise
Android
Mobile
Legal
Mobile Advertising
Platforms
Cannabis
Hospitality
Biotechnology
Travel
Fitness
Recruiting
Automotive
Medical Device
Social
Crowdfunding
Wine And Spirits
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Film
Life Science
Theatre
Non Profit
Sporting Goods
Renewable Energy
SaaS
Restaurants
Social Impact
Celebrity
Software
Agriculture (agtech)
Cryptocurrency
Machine Learning
Media (entertainment)
Blockchain
Facebook
Investors by country
United Kingdom
Germany
India
United States
Ireland
South Korea
Canada
Australia
New Zealand
Middle East
Oceania
Europe
Asia
South Africa
Armenia
Brazil
Qatar
Indonesia
Spain
China
Saudi Arabia
Sri Lanka
Vietnam
Africa
LATAM
Japan
Singapore
Finland
Estonia
Hungary
Ethiopia
Hong Kong
Georgia
Egypt
Ecuador
Denmark
France
Faroe Islands
Ghana
Croatia
Gibraltar
Bulgaria
Chile
Belize
Barbados
Costa Rica
Greece
Belgium
Bahrain
Belarus
Bermuda
Czech Republic
Algeria
Mali
Mexico
Liberia
Israel
Philippines
Malaysia
Italy
Lithuania
Liechtenstein
Kuwait
Norway
Morocco
Myanmar
Lebanon
Mauritius
Peru
Jersey
Panama
Malta
Nicaragua
Sweden
El Salvador
Uruguay
Portugal
Zambia
Ukraine
Uzbekistan
Senegal
Seychelles
Venezuela
Tajikistan
Taiwan
Serbia
Uganda
Sierra Leone
Turkey
Thailand
Tunisia
San Marino
Rwanda
Puerto Rico
Poland
Russian Federation
Tanzania
Slovenia
Zimbabwe
Togo
Dominican Republic
Azerbaijan
Nigeria
Bahamas
Namibia
Iceland
Iraq
United Arab Emirates
Jamaica
Honduras
Isle of Man
Bolivia
Luxembourg
Albania
Pakistan
Grenada
Romania
Jordan
Argentina
Bangladesh
Kazakhstan
Kenya
Cayman Islands
Cambodia
Oman
Cyprus
Latvia
Marshall Islands
Austria
Cameroon
Switzerland
Colombia
Guatemala
VC (Venture Capital) Funds in United States by industry
Transportation
Enterprise
FinTech
Health Care
Biotech
Consumer
Climate
Impact
Energy
Sustainability
Proptech
Marketplace
SaaS
Community
Artificial intelligence
Gaming
Venture Capital
Crowdfunding
Retail
Financial Services
LGBT
Oil and Gas
Film
Publishing
Cryptocurrency
Education
Payments
Food and Beverage
Wine And Spirits
Video Games
Restaurants
Medical
Franchise
Wellness
EdTech
Email
Hardware
Social Media
Manufacturing
Digital Media
Celebrity
Art
Theatre
Blockchain
Android
Mobile
Social Impact
Google
Legal
Software
Non Profit
Local
Enterprise Software
Finance
Sports
eSports
CleanTech
Hospitality
Automotive
InsurTech
Travel
Biotechnology
Cannabis
Platforms
Mobile Advertising
Real Estate
Infrastructure
Fashion
Social
Web3
Life Science
Photography
Sporting Goods
Big Data
Clean Energy
Construction
Medical Device
Mobile Apps
B2B
Social Network
Fitness
Renewable Energy
Music
Internet
Beauty
Agriculture (agtech)
Media (entertainment)
Facebook
Organic Food
Machine Learning
Recruiting